Genmab A/S Files 6-K, Incorporates into S-8 Filings
Ticker: GNMSF · Form: 6-K · Filed: Mar 4, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, registration-statement, administrative
TL;DR
Genmab 6-K filed March 4, 2024, incorporates into S-8s. No new material info.
AI Summary
Genmab A/S filed a Form 6-K on March 4, 2024, for the month of March 2024. This report is incorporated by reference into Genmab's existing S-8 registration statements (File Nos. 333-232693, 333-232693 and 333-262970). The filing does not contain specific financial figures or operational updates beyond its incorporation into registration statements.
Why It Matters
This filing serves to update registration statements, ensuring compliance and potentially facilitating the issuance of new securities or employee stock options.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates previous information into existing registration statements, with no new material disclosures.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 333-232693 (dollar_amount) — S-8 Registration Statement File Number
- 333-262970 (dollar_amount) — S-8 Registration Statement File Number
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The Form 6-K filed on March 4, 2024, is a report for the month of March 2024 and is incorporated by reference into Genmab A/S's existing registration statements on Form S-8.
Which specific registration statements are being updated by this filing?
This Form 6-K is incorporated by reference into Genmab A/S's registration statements on Form S-8 with File Numbers 333-232693, 333-232693, and 333-262970.
What is the filing date of this Form 6-K?
The Form 6-K was filed on March 4, 2024.
Does this filing contain new financial information for Genmab A/S?
The provided text of the filing does not contain specific new financial figures or operational updates; it primarily serves to incorporate information into existing registration statements.
What is the principal executive office address for Genmab A/S?
The address of Genmab A/S's principal executive offices is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 232 words · 1 min read · ~1 pages · Grade level 15.1 · Accepted 2024-03-01 18:38:37
Filing Documents
- tmb-20240301x6k.htm (6-K) — 18KB
- tmb-20240301xex99d1.htm (EX-99.1) — 141KB
- tmb-20240301xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-002285.txt ( ) — 168KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-232693 and 333-262970 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: MARCH 02, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated March 02, 2024: Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons